The aim of the 5th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with the theme, having over three-quarters of the presentations focussed on case studies. The conference will include successful examples from all types of fragment-based approaches, including high concentration, NMR, SPR and X-ray screening.
Deadlines
Useful links
Downloads
-
Fragments and the bigger picture, Mike Hann, GlaxoSmithKline
-
Introduction to FBDD, Thorsten Nowak, C4X Discovery, and Mike Hann, GSK
-
Identifying hits: fragment screening libraries and methods, Samantha Hughes, AZ
-
Hit optimisation using fragments, Mark Whittaker, Evotec
-
Second announcement
